Holen Sie sich die Stockscreener-App
0.5795
0.33%
-0.0019
Schlusskurs vom Vortag:
$0.5814
Offen:
$0.59
24-Stunden-Volumen:
1.45M
Relative Volume:
2.77
Marktkapitalisierung:
$16.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-55.73M
KGV:
-0.1796
EPS:
-3.2274
Netto-Cashflow:
$-68.87M
1W Leistung:
+35.30%
1M Leistung:
+24.81%
6M Leistung:
-61.62%
1J Leistung:
-83.68%
1-Tages-Spanne:
$0.5414
$0.68
1-Wochen-Bereich:
$0.4231
$0.68
52-Wochen-Spanne:
$0.3151
$3.6487
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Firmenname
Jasper Therapeutics Inc
Sektor
Branche
Telefon
(650) 549-1400
Adresse
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
0.5795 | 16.23M | 0 | -55.73M | -68.87M | -3.2274 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-23 | Fortgesetzt | UBS | Neutral |
| 2026-01-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2025-07-08 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-09-09 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-08 | Eingeleitet | BTIG Research | Buy |
| 2024-06-27 | Eingeleitet | Stifel | Buy |
| 2024-05-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-03 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-11 | Eingeleitet | CapitalOne | Overweight |
| 2022-02-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Eingeleitet | Credit Suisse | Outperform |
| 2021-10-21 | Eingeleitet | William Blair | Outperform |
| 2021-10-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-13 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Jasper Therapeutics Inc Aktie (JSPR) Neueste Nachrichten
Jasper Therapeutics (NASDAQ: JSPR) sees Millennium group report 1.7% equity stake - Stock Titan
Price to earnings forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW - TradingView
Jasper Therapeutics (JSPR) Stock Rebounds 6.83% as Biotech Sentiment ImprovesPCR Extreme - dars.gov.et
Jasper Therapeutics stock holds the focus. Company profile stays central. - ad-hoc-news.de
Enterprise value to EBIT forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW - TradingView
Price to earnings forward of Jasper Therapeutics, Inc. – NASDAQ:JSPR - TradingView
JSPRJasper Therapeutics Inc Options - Finviz
Japer Therapeutics, Inc.Warrant 2021-01.12.26 on Jasper Therapeutics Financial Disclosures & SEC Filings - TradingView
Insider Traders Lose US$287k As Jasper Therapeutics Drops - simplywall.st
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
JSPR Q1 2026 Earnings: Significant EPS Beat Highlights Continued Cost DisciplineEarnings Call Highlights - dars.gov.et
Price to earnings forward of Jasper Therapeutics, Inc. – BOATS:JSPRW - TradingView
Jasper Therapeutics Inc (JSPRW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jasper Therapeutics Inc (JSPRW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jasper Therapeutics StockAnalyst consensus and weekly review - Ad-hoc-news.de
Jasper Therapeutics Inc (JSPR) Institutional Confidence - TradingKey
Jasper Therapeutics Inc (JSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jasper Therapeutics Inc (JSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jasper Therapeutics Inc (JSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jasper Therapeutics Inc (JSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jasper Therapeutics Inc (JSPRW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jasper Therapeutics Inc (JSPRW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Jasper Therapeutics Inc (JSPRW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jasper Therapeutics Inc (JSPRW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jasper Therapeutics Inc (JSPRW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jasper Therapeutics Inc (JSPRW) Institutional Confidence - TradingKey
Jasper Therapeutics Inc (JSPRW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long John Silver's Franchisee To Liquidate - Dailyhunt
Jasper Therapeutics Inc (JSPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jasper Therapeutics Inc (JSPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Jasper Therapeutics Inc (JSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jasper Therapeutics Inc (JSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
JSPR Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
JSPR | Jasper Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Jasper Therapeutics (NASDAQ: JSPR) outlines 2026 virtual meeting, board and pay votes - Stock Titan
Jasper Therapeutics (JSPR) Edges Lower, Testing Key Support Near $0.44FRAMA Signal - newsline.com
Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Jasper Therapeutics (JSPR) Hovers Near Support After Marginal DeclineAD Line Divergence - dars.gov.et
Nasdaq warns Jasper Therapeutics (JSPR) on sub-$1 bid, delisting risk noted - Stock Titan
Jasper Therapeutics (JSPR) Edges Higher Amid Tight Trading RangeAndrews Pitchfork - newsline.com
symbol__ Stock Quote Price and Forecast - CNN
JSPR Q1 2026 Earnings: Massive EPS Beat with -$0.04 vs -$0.4965 Estimate; Stock RisesEarnings Power Value - newsline.com
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long - Benzinga
Bears are losing control over Jasper Therapeutics (JSPR), here's why it's a 'buy' now - MSN
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now - sharewise.com
Jasper Therapeutics Initiates Review of Strategic Alternatives to Maximize Shareholder Value - marketscreener.com
Jasper Therapeutics Explores Sale, Merger and Other Strategic Alternatives - Moomoo
Jasper Therapeutics Weighs Sale as Cash Dwindles, Drug's Fate Uncertain - BriefGlance
Jasper Therapeutics Initiates Strategic Alternatives Review to Maximize Shareholder Value Amid Mast Cell Disease Therapy Focus 1 - Minichart
Jasper Therapeutics Launches Strategic Alternatives Review Amid Uncertainty - TipRanks
Jasper Therapeutics explores strategic alternatives By Investing.com - Investing.com South Africa
Finanzdaten der Jasper Therapeutics Inc-Aktie (JSPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):